Cure My Disease

Don't miss your cure!

 Log in / Sign up

Menstrual cycle forces women with diabetes to hack their insulin pumps

NCT ID NCT07696780

Knowledge-focused Sponsor: DCB Research AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study investigates how women with type 1 diabetes manually adjust their automated insulin delivery (AID) systems to manage blood sugar changes during their menstrual cycle. Researchers will interview 69 women to catalog strategies like entering fake carbohydrates or changing insulin settings, and measure how often these adjustments are needed. The goal is to gather data that could help design smarter AID algorithms that automatically account for menstrual cycle-related insulin sensitivity shifts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help design automated insulin delivery systems that automatically adjust for menstrual cycle changes, reducing the burden on women with type 1 diabetes.
What could go wrong
This is an observational study with a small sample size (69 participants), so findings may not apply to all women. It identifies problems but does not test a solution.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

69 people

The number who actually took part.

Started

Oct 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with type 1 diabetes and menstrual cycle using AID system

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years old * Good knowledge of English or German * Type 1 diabetes since \>3 years * Regular menstrual cycle (24-35 days) since \>2 years * Using one of the following AID systems: Tandem t-slim:X2 with Control-IQ; Medtronic 780G; DBLG1 (Kaleido, AkkuChek Insight); CAMAPS FX (Ypsopump, Dana); Omnipod 5; AAPS DIY; IAPS DIY; Loop DIY

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • DCB Research AG

    Bern, Canton of Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.